FUSION PHARMACEUTICALS INC (FUSN) Stock Overview
USA - NASDAQ:FUSN - CA36118A1003 - Common Stock
FUSN Key Statistics, Chart & Performance
The current stock price of FUSN is 21.55 USD. In the past month the price increased by 0.47%. In the past year, price increased by 335.35%.
FUSN Latest News, Press Relases and Analysis
FUSN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.83B | ||
| AMGN | AMGEN INC | 13.35 | 156.75B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 149.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 107.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 62.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.73B | ||
| ARGX | ARGENX SE - ADR | 90.1 | 51.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.09 | 34.65B | ||
| INSM | INSMED INC | N/A | 34.67B | ||
| NTRA | NATERA INC | N/A | 26.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.49B | ||
| BIIB | BIOGEN INC | 9.4 | 22.05B |
Related stock screener links
About FUSN
Company Profile
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Hamilton Ontario, Ontario and currently employs 102 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing radiopharmaceuticals as precision medicines. The company has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
Company Info
FUSION PHARMACEUTICALS INC
270 Longwood Rd. S
Hamilton Ontario ONTARIO L8P 0A6 CA
CEO: John Valliant
Employees: 102
Phone: 12897990891
FUSION PHARMACEUTICALS INC / FUSN FAQ
What does FUSION PHARMACEUTICALS INC do?
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Hamilton Ontario, Ontario and currently employs 102 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing radiopharmaceuticals as precision medicines. The company has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
What is the current price of FUSN stock?
The current stock price of FUSN is 21.55 USD. The price increased by 0.14% in the last trading session.
Does FUSION PHARMACEUTICALS INC pay dividends?
FUSN does not pay a dividend.
What is the ChartMill technical and fundamental rating of FUSN stock?
FUSN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about FUSION PHARMACEUTICALS INC (FUSN) stock?
18 analysts have analysed FUSN and the average price target is 21.55 USD. This implies a price decrease of -0.01% is expected in the next year compared to the current price of 21.55.
What is the ownership structure of FUSION PHARMACEUTICALS INC (FUSN)?
You can find the ownership structure of FUSION PHARMACEUTICALS INC (FUSN) on the Ownership tab.
FUSN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FUSN. When comparing the yearly performance of all stocks, FUSN is one of the better performing stocks in the market, outperforming 99.5% of all stocks.
FUSN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FUSN. While FUSN seems to be doing ok healthwise, there are quite some concerns on its profitability.
FUSN Financial Highlights
Over the last trailing twelve months FUSN reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 28.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.2% | ||
| ROE | -43.12% | ||
| Debt/Equity | 0.21 |
FUSN Forecast & Estimates
18 analysts have analysed FUSN and the average price target is 21.55 USD. This implies a price decrease of -0.01% is expected in the next year compared to the current price of 21.55.
For the next year, analysts expect an EPS growth of -0.46% and a revenue growth -82.55% for FUSN